
Johan A Karlsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4748758/publications.pdf Version: 2024-02-01



IOHAN A KADISSON

#	Article	IF	CITATIONS
1	Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. Rheumatology, 2023, 62, 647-658.	0.9	6
2	Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register. Scandinavian Journal of Rheumatology, 2023, 52, 374-384.	0.6	7
3	How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort. Scandinavian Journal of Rheumatology, 2023, 52, 364-373.	0.6	1
4	<scp>Oneâ€Year</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care and Research, 2022, 74, 748-758.	1.5	15
5	Realâ€World Six―and Twelveâ€Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	1.5	20
6	Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. Arthritis Research and Therapy, 2022, 24, 42.	1.6	12
7	Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis: Results From the SPARTAKUS Cohort. Journal of Rheumatology, 2021, 48, 1672-1679.	1.0	17
8	Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial. Arthritis Care and Research, 2021, 73, 1312-1321.	1.5	21
9	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: aÂNordic population-based cohort study. Rheumatology, 2021, 60, 140-146.	0.9	4
10	Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. Rheumatology, 2021, 60, 2217-2222.	0.9	0
11	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1116-1123.	0.5	13
12	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology, 2021, 60, 3635-3645.	0.9	14
13	Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?. Annals of the Rheumatic Diseases, 2020, 79, 159-161.	0.5	15
14	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. Journal of Rheumatology, 2019, 46, 555-563.	1.0	17
15	Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group. Journal of Rheumatology, 2019, 46, 1401-1405.	1.0	13
16	THU0149â€PRIME-BOOSTER RESPONSE TO PNEUMOCOCCAL CONJUGATE AND POLYSACCHARIDE VACCINES PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. , 2019, , .	IN	0
17	THU0073â€HAVE THE CLINICAL CHARACTERISTICS OF RHEUMATOID ARTHRITIS AT PRESENTATION BECOME MILDER OVER TIME? RESULTS FROM A NATIONWIDE STUDY OVER THREE DECADES IN SWEDEN. , 2019, , .		0
18	SAT0336â€CLINICAL DIAGNOSES OF AXIAL SPONDYLOARTHRITIS SHOW A HIGH OVERALL CONCORDANCE W CLASSIFICATION CRITERIA FULFILMENT, BUT ARE LESS CONSISTENT FOR DIFFERENTIATION BETWEEN SUBTYPES IN ESTABLISHED AXIAL DISEASE: RESULTS FROM THE SPARTAKUS COHORT. , 2019, , .	ΊΤΗ	1

#	Article	IF	CITATIONS
19	THU0090â€MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE. , 2019, , .	A	Ο
20	Response to: â€~response to: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft et al Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216752.	0.5	1
21	Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Research and Therapy, 2019, 21, 266.	1.6	17
22	Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort. Rheumatology, 2019, 58, 1176-1187.	0.9	18
23	Patientâ€Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologicsâ€Treated Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 1712-1716.	1.5	13
24	Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. Rheumatology, 2017, 56, kew473.	0.9	6
25	A Multiâ€Biomarker Disease Activity Score and the Choice of Secondâ€Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. Arthritis and Rheumatology, 2017, 69, 953-963.	2.9	27
26	Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open, 2016, 2, e000197.	1.8	21
27	Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden. Journal of Rheumatology, 2016, 43, 1292-1299.	1.0	17
28	EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Research and Therapy, 2016, 18, 51.	1.6	7
29	Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Annals of the Rheumatic Diseases, 2016, 75, 356-361.	0.5	28
30	Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Research and Therapy, 2015, 17, 378.	1.6	53
31	Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Diseases, 2015, 74, 1094-1101.	0.5	43
32	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Annals of the Rheumatic Diseases, 2013, 72, 1927-1933.	0.5	25
33	National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2011, 70, 2163-2166.	0.5	37